257 related articles for article (PubMed ID: 29478795)
1. Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy.
Fritsche MR; Watchmaker JM; Lipnik AJ; Baker JC; Geevarghese S; Banovac F; Omary RA; Brown DB
J Vasc Interv Radiol; 2018 Apr; 29(4):550-555. PubMed ID: 29478795
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience.
Idilman I; Peynircioğlu B; Cil BE; Doğanay Erdoğan B; Yalçın S; Bayraktar Y; Kav T; Altundağ K; Balkancı F
Turk J Gastroenterol; 2013; 24(2):141-7. PubMed ID: 23934461
[TBL] [Abstract][Full Text] [Related]
3. Six-Year Evaluation of Same-Day Discharge following Conventional Transarterial Chemoembolization of Hepatocellular Carcinoma.
Hund HC; Frantz SK; Wu H; Adeniran OR; Wong TY; Borgmann AJ; Matsuoka L; Geevarghese S; Alexopoulos S; Shingina A; Meranze SG; Baker JC; Garbett S; Brown DB
J Vasc Interv Radiol; 2023 Mar; 34(3):378-385. PubMed ID: 36481322
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
5. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
Mouli SK; Hickey R; Thornburg B; Sato KT; Desai K; Gabr A; Kallini JR; Niemeri H; Kircher S; Mulcahy MF; Benson Iii AB; Gupta R; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355
[TBL] [Abstract][Full Text] [Related]
6. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
[TBL] [Abstract][Full Text] [Related]
7. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program.
Nasser F; Cavalcante RN; Galastri FL; de Rezende MB; Felga GG; Travassos FB; De Fina B; Affonso BB
J Vasc Interv Radiol; 2014 Jul; 25(7):1012-7. PubMed ID: 24704346
[TBL] [Abstract][Full Text] [Related]
8. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
[TBL] [Abstract][Full Text] [Related]
9. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
10. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J
J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
[TBL] [Abstract][Full Text] [Related]
13. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
14. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
15. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
El Khaddari S; Gaudin JL; Abidi H; Picaud G; Rode A; Souquet JC
Gastroenterol Clin Biol; 2002; 26(8-9):728-34. PubMed ID: 12434077
[TBL] [Abstract][Full Text] [Related]
16. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
17. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocol.
Vogl TJ; Oppermann E; Qian J; Imlau U; Tran A; Hamidavi Y; Korkusuz H; Bechstein WO; Nour-Eldin NE; Gruber-Rouh T; Hammerstingl R; Naguib NN
BMC Cancer; 2016 May; 16():325. PubMed ID: 27215551
[TBL] [Abstract][Full Text] [Related]
20. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
